Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer

Area of Science:

• Oncology
• Urology

Background:

• Prostate cancer is a leading cause of cancer death in US men.
• Recent therapeutic advances have improved metastatic castration-resistant prostate cancer (mCRPC) treatment.
• Accurate disease progression assessment is crucial for effective mCRPC management.

Purpose of the Study:

• To redefine disease progression criteria in prostate cancer.
• To emphasize the importance of clinical and radiographic evidence over prostate-specific antigen (PSA) alone.

Main Methods:

• Review of current prostate cancer progression definitions.
• Analysis of the role of PSA in disease monitoring.
• Integration of clinical and radiographic findings in progression assessment.

Main Results:

• Prostate-specific antigen (PSA) levels alone are insufficient to define disease progression.
• Clinical symptoms and radiographic evidence are essential components of progression assessment.
• A multi-faceted approach combining PSA with clinical and imaging data is superior.

Conclusions:

• Disease progression in prostate cancer requires evaluation beyond PSA.
• Clinical and radiographic data are critical for accurate staging and treatment decisions.
• Future management strategies should incorporate comprehensive assessment methods.